[PDF][PDF] PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of …
AV Lænkholm, MB Jensen, JO Eriksen… - Journal of Clinical …, 2018 - prosigna.com
Journal of Clinical Oncology, 2018•prosigna.com
Purpose The PAM50-based Prosigna risk of recurrence (ROR) score has been validated in
randomized clinical trials to predict 10-year distant recurrence (DR). The value of Prosigna
for predicting DR was examined in a comprehensive nationwide Danish cohort consisting of
postmenopausal women with hormone receptor–positive early breast cancer treated with 5
years of endocrine therapy alone.
randomized clinical trials to predict 10-year distant recurrence (DR). The value of Prosigna
for predicting DR was examined in a comprehensive nationwide Danish cohort consisting of
postmenopausal women with hormone receptor–positive early breast cancer treated with 5
years of endocrine therapy alone.
Purpose
The PAM50-based Prosigna risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR). The value of Prosigna for predicting DR was examined in a comprehensive nationwide Danish cohort consisting of postmenopausal women with hormone receptor–positive early breast cancer treated with 5 years of endocrine therapy alone.
prosigna.com
